Vanda Pharmaceuticals Bets Big on Growth Pipeline

Vanda Pharmaceuticals ((VNDA)) has held its Q1 earnings call. Read on for the main highlights of the call.

Vanda Pharmaceuticals’ latest earnings call struck a cautiously optimistic tone as management balanced strong product momentum with mounting financial strain. Executives highlighted robust growth in core psychiatry brands, a novel launch strategy for Nirius, and multiple regulatory catalysts, but acknowledged rising losses, heavier cash burn and continued erosion in the legacy Hetlioz franchise.

Total Revenue Growth and Raised Guidance

Vanda reported Q1 2026 net product sales of $51.7 million, up 3% year over year despite typical first‑quarter insurance headwinds. Management raised full‑year 2026 revenue guidance to a range of $240 million to $290 million, with the midpoint implying roughly 23% growth versus 2025 and signaling confidence in both existing and new product contributions.

Fanapt Commercial Momentum

Fanapt remained the growth engine, generating $29.6 million in Q1 sales, a 26% year‑over‑year increase supported by strong prescription trends. Total prescriptions rose 32% and new prescriptions jumped 76%, with weekly TRx reaching an eleven‑year high, underpinning guidance of $150 million to $170 million for 2026, or about 36% growth at the midpoint.

Nirius U.S. Launch and Innovative DTC Model

Vanda highlighted the nationwide launch of Nirius through a direct‑to‑consumer platform with a cash‑pay model, positioning it as the first new prescription option in decades for preventing motion‑induced vomiting in adults. The company introduced 2026 Nirius revenue guidance of $10 million to $30 million and set a wholesale price of $255 per capsule, with a sharply discounted cash‑pay option to drive early adoption.

Regulatory and Pipeline Progress — Dysanti Approval

The call underscored a key regulatory win with FDA approval of Dysanti for bipolar I disorder and schizophrenia, backed by long‑dated patents and data exclusivity into the next decade. Management expects Dysanti to become commercially available in the back half of 2026, positioning it as a future revenue pillar as the company builds out launch infrastructure.

Imsidolimab Regulatory Milestone and Publication

In immunodermatology, the FDA accepted the biologics license application for imsidolimab in generalized pustular psoriasis, setting up a December 12, 2026 decision date. Vanda emphasized that pivotal data were recently published in NEJM Evidence and noted preparations for potential launches across the U.S., Europe and Japan, signaling an emerging diversification beyond psychiatry.

Late‑Stage Clinical Readouts Expected

Investors were reminded of several late‑stage catalysts, including a Phase 3 Dysanti study in adjunctive major depressive disorder with data expected in early 2027. Additional Phase 3 readouts for Nirius in GLP‑1‑induced vomiting and VQW‑765 in social anxiety are planned by 2026, creating a clustered series of events that could materially reshape the company’s mid‑term growth profile.

Commercial Infrastructure Expansion

To support its expanding portfolio, Vanda nearly doubled the Fanapt sales force from roughly 160 to about 300 representatives by the end of 2025. The company reported that face‑to‑face calls in Q1 2026 were more than 80% higher than a year ago, arguing that this commercial build‑out is already translating into stronger prescription growth and brand visibility.

Widening Net Loss and Higher Operating Expenses

The growth push came at a cost, as Q1 2026 net loss widened to $48.6 million from $29.5 million a year earlier. Operating expenses climbed to $101.9 million, driven by higher selling and marketing spend related to launches and field force expansion, along with elevated legal costs, reinforcing that the current strategy is investment‑heavy.

Cash Position and Increased Cash Burn

Vanda ended the quarter with $202.3 million in cash, equivalents and marketable securities, a decline of $61.5 million since year‑end 2025. Management attributed the drop to the quarterly loss, milestone and manufacturing payments and seasonal compensation, and cautioned that 2026 cash burn is likely to exceed 2025 levels, a key consideration for shareholders.

Hetlioz Decline from Generic Competition

Legacy product Hetlioz continued to face pressure, with Q1 sales of $15.9 million falling 24% year over year and slipping modestly versus the prior quarter. Management warned that U.S. generic competition could drive further, potentially significant declines, underscoring the urgency of replacing this revenue with newer assets.

Quarterly Sequential Pressure and Insurance Seasonality

Sequentially, total revenues declined 10% compared with Q4 2025, a trend the company tied to annual insurance plan disruptions and deductible resets. Fanapt sales fell 11% quarter over quarter and total prescriptions were down 1%, though management framed this as a recurring seasonal pattern rather than a structural slowdown.

Ponvory Variability and Disputes

Ponvory sales reached $6.2 million in Q1, up 10% versus the prior year but down 18% from Q4, despite management indicating that underlying patient demand remained flat quarter over quarter. The company also highlighted that some variable consideration related to Ponvory is under dispute, affecting roughly $3 million of previously recognized 2024 revenue and adding an element of uncertainty.

Development & Recruitment Challenges for Long‑Acting Iloperidone

Vanda flagged emerging challenges in its long‑acting iloperidone relapse‑prevention study, which is recruiting slowly in the U.S. and facing lower‑than‑expected placebo relapse rates. Management suggested that after further FDA discussions the development plan may need modification, introducing additional timing and outcome risk for this potential extension of the Fanapt franchise.

Forward‑Looking Guidance and Outlook

Updated 2026 guidance reflects management’s confidence in the growth trajectory, with total revenue now expected between $240 million and $290 million and Fanapt targeted at $150 million to $170 million, assuming steady gross‑to‑net dynamics. The outlook embeds high single‑digit to high‑teens sequential TRx growth scenarios for Fanapt, incremental contributions from Nirius and other products, and an explicit warning that cash burn will likely rise as the company invests through this expansion phase.

Vanda’s earnings call painted a picture of a company in transition, leaning into new launches and late‑stage assets to offset erosion in older products and justify heavier spending. For investors, the thesis now hinges on whether Fanapt momentum, Nirius uptake and upcoming regulatory decisions can materialize fast enough to outpace growing losses and cash usage, a trade‑off that will keep execution under close watch.